Citations

Clear

13603 citation(s) found for "_, _".

Homelessness and Cancer: A Multi-Site, Mixed Methods Study of Delayed or No Cancer Therapy
Haemmerle, Robert , Fee-Schroeder, Kelliann C., Phelan, Lynn, Jatoi, Aminah , Cathcart-Rake, Elizabeth , Haemmerle, Robert J , Fee-Schroeder, Kelliann, Cathcart-Rake, Elizabeth J , Phelan, Lynn

Mayo Clinic

American Journal of Hospice and Palliative Medicine® | March 18, 2025 | Volume: 43 | Issue: 2 | Pages: 179-187

10.1177/10499091251325231 | PMID 40099521 Get It

Background: Patients who experience homelessness manifest poor cancer outcomes, often because of treatment delays. Few studies have used mixed methods to learn what happens at the patient and health care staff level to explain these delays. Methods: This single-institution, multi-site study interrogated the entire medical record system (thousands of patients annually) for homelessness and cancer diagnoses from January 1, 2019, through October 10, 2023. Records were abstracted for relevant quantitative and qualitative data; rigorous methods were used to analyze, integrate, and report findings. Results: Forty-three patients with a median age of 58 years (range: 32, 73 years) and 34 (79%) assigned male sex at birth are the focus of this report. The most common cancers include hematologic (n = 8), gastrointestinal (n = 8), and genitourinary (n = 8). Thirty-five patients (81%) initiated cancer therapy, and 27 (63%) manifested treatment delay (>4 weeks post-diagnosis). The median time to cancer therapy was 9 weeks (95% confidence interval: 4.6, 12 weeks). Qualitative themes that explain delays are as follows: (1) logistical challenges in communication between the patient and health care team (“lack of a cell phone”); (2) patient reluctance to receive care (“patient elected to leave Against Medical Advice”); and (3) medical challenges in providing care (“he was hospitalized after being found down and hypotensive”). Conclusions: This study confirms that initiation of cancer therapy is often delayed in patients who experience homelessness. It sheds light on reasons for delay – for example, lack of phone access, an observation which suggests that perhaps provision of a burner phone might help some patients.
Pain and Hardware Removal After Tibial Tubercle Osteotomy: Incidence, Associated Factors, and Outcomes
Davis, Michelle A. , Meta, Fabien , Dancy, Malik E. , Scott, Parker, Tagliero, Adam J. , Krych, Aaron J. , Hevesi, Mario , Okoroha, Kelechi R. , Scott, Parker A, Tagliero, Adam , Krych, Aaron J , Hevesi, Mario , Okoroha, Kelechi R , Davis, Michelle, Pan, Xuankang

Mayo Clinic

Orthopaedic Journal of Sports Medicine | March 17, 2025 | Volume: 13 | Issue: 3 | Pages: No page available

10.1177/23259671251324481 | PMID 40104600 Get It

Background: While patients may report painful or prominent hardware after tibial tubercle osteotomy (TTO), little is known about the frequency, associated factors, and outcomes after removal of symptomatic hardware. Purpose/Hypothesis: The purpose was to investigate the incidence of hardware removal after TTO due to pain or complications, factors associated with hardware removal, and postoperative outcomes after removal. It was hypothesized that clinical outcomes would be similar between patients who underwent TTO without hardware removal and those who underwent TTOs and subsequently hardware removal. Study Design: Case-control study; Level of evidence, 3. Methods: A retrospective analysis was performed on patients who underwent TTO at a single institution from 2000 to 2023. Age at the time of the index surgery, sex, race, body mass index, number and size of screws, tibial tubercle–trochlear groove distance, and reason for hardware removal were collected retrospectively. Knee radiographs were reviewed for measurement of soft tissue–hardware distance. Patients were contacted via email to capture final patient-reported outcome measures (PROMs). A univariate logistic regression model was used to determine factors associated with hardware removal. Results: A total of 152 patients representing 171 knees were included. Of the overall cohort, 38 knees (22.2%) in 32 patients underwent TTO with subsequent hardware removal. The most common reason for hardware removal was anterior knee pain (79%). Compared with patients aged 11 to 20 years, patients aged 21 to 30 years demonstrated higher odds of undergoing hardware removal (OR, 3.67; 95% CI, 1.51-9.44; P = .009). Compared with a soft tissue–hardware distance of 0 to 4.9 mm, a distance of 10.0 to 14.9 mm demonstrated lower odds of hardware removal (OR, 0.24; 95% CI, 0.07-0.84; P = .027). Visual analog scale scores (0-10 scale) improved by a mean of 3.6 points after hardware removal ( P = .003). In patients undergoing hardware removal for pain, no difference in final PROMs was found compared with patients who underwent TTO without hardware removal. Conclusion: Hardware removal in patients undergoing TTO was mainly attributed to hardware-related pain/irritation. On average, pain scores improved after hardware removal. There was no difference in final PROMs between patients who had their hardware removed due to pain (eg, without any clinically relevant concomitant pathology) and patients who did not require hardware removal. Size and number of screws were not associated with a subsequent hardware removal procedure. The thickness of the soft tissue envelope overlying implanted hardware was inconsistently associated with lower odds of hardware removal.
Novel Diagnosis of Isolated Cardiac Erdheim–Chester Disease by Interatrial Biopsy Using Frozen Section Examination
Singh, Jasraj , Neidert, Newton B. , Anderson, Jason H. , Layman, Andrew J. , Rech, Karen L. , Go, Ronald S. , Breen, William G. , Young, Phillip M. , Young, Jason R. , Koster, Matthew J. , Go, Ronald S , Koster, Matthew J , Young, Jason R , Rech, Karen , Anderson, Jason , Layman, Andrew J.

Mayo Clinic

Interventional Cardiology: Reviews, Research, Resources | March 17, 2025 | Volume: 20 | Issue: No issue available | Pages: No page available

10.15420/icr.2024.32 | PMID 40171021 Get It

Erdheim–Chester disease (ECD) is a rare non-Langerhans cell histiocytosis characterised by multiorgan pathological histiocytic infiltration. Cardiac involvement occurs in 40–75% of patients and increases mortality. A 55-year-old woman with chest pain and dyspnoea was found to have an interatrial septal mass and aortitis suspicious for ECD without other organ involvement. After two inadequate transcatheter interatrial biopsies were obtained using ultrasound guidance alone, diagnostic samples were successfully obtained using intraprocedural frozen section examination. The patient started genotype-targeted treatment with good response. Biopsy confirmation of ECD is required to guide treatment; however, cardiac biopsies are uncommonly performed when other organs are affected. Our unique case of isolated cardiovascular involvement highlights how frozen sectioning with multimodal intraprocedural imaging guidance can improve diagnostic yield of endomyocardial biopsies. It also highlights how diagnosis of rare conditions requires careful multidisciplinary evaluation of affected organs, procedural risk and diagnostic yield. The use of frozen sectioning can improve diagnostic yield of endomyocardial biopsies.
HIV mortality trends among the United States population, from 1999–2023: a CDC wonder database study
Ekpendu, Abuoma Cherry , Asghar, Muhammad Sohaib , Shaik, Afsana Ansari, Khalid, Muhammad Zain , Duharte, Maria, Duharte-Vidaurre, Luis, Brands, Chad K., Asghar, Muhammad S , Shaik, Afsana Ansari, Hegazi, Moustafa

Mayo Clinic

Infectious Diseases | March 17, 2025 | Volume: 57 | Issue: 5 | Pages: 444-463

10.1080/23744235.2025.2477700 | PMID 40094274 Get It

Waldenström Macroglobulinemia: 2025 Update on Diagnosis, Risk Stratification, and Management
Gertz, Morie A. , Gertz, Morie A

Mayo Clinic

American Journal of Hematology | March 17, 2025 | Volume: 100 | Issue: 6 | Pages: 1061-1073

10.1002/ajh.27666 | PMID 40095219 Get It

ABSTRACT Disease Overview Waldenström macroglobulinemia (WM) is a lymphoplasmacytic lymphoma with immunoglobulin M (IgM) monoclonal protein. Clinical features include anemia, thrombocytopenia, hepatosplenomegaly, lymphadenopathy, and rarely hyperviscosity. Diagnosis The presence of IgM monoclonal protein associated with ≥ 10% clonal lymphoplasmacytic cells in bone marrow confirms the diagnosis. The L265P mutation in MYD88 is detectable in more than 90% of patients and is found in most IgM MGUS patients. MYD88 is not required for the diagnosis. Risk Stratification Age, albumin, hemoglobin level, platelet count, β 2 microglobulin, Lactate dehydrogenase (LDH), and monoclonal IgM concentrations are characteristics that are predictive of outcomes. Risk‐Adapted Therapy Not all patients who fulfill WM criteria require therapy; these patients can be observed until symptoms develop. Rituximab‐monotherapy is inferior to combination regimens. Recommended first‐line therapy can be chemoimmunotherapy or a covalent Bruton tyrosine kinase inhibitor. The preferred Mayo Clinic induction is either rituximab and bendamustine (without rituximab maintenance) or zanubrutinib. Management of Refractory Disease Bortezomib, cyclophosphamide, fludarabine, thalidomide, everolimus, pirtobrutinib, carfilzomib, lenalidomide, bendamustine, and venetoclax have all been shown to have activity in relapsed WM. Given WM's natural history, the reduction of therapy toxicity is an important part of treatment selection. Most patients succumb to causes unrelated to macroglobulinemia.
Belumosudil in diffuse cutaneous systemic sclerosis: a randomized, double-blind, open-label extension, placebo-controlled, phase 2 study
Chung, Leland W.K. , Steen, Virginia , Furst, Daniel E. , Castelino, Flavia V. , Trojanowski, Marcin A. , Domsic, Robyn T. , Katsumoto, Tamiko R. , Goulaouic, Hélène , Wang, Hong , Espinasse, Melanie, El‐Chemaly, Souheil , Wang, Rui , Chung, Lorinda , Furst, Daniel E , Domsic, Robyn T , Katsumoto, Tamiko R , Wang, Rui , Silver, Richard M. , Spiera, Robert , Rodríguez-Pla, Alicia

Mayo Clinic

Rheumatology | March 15, 2025 | Volume: 64 | Issue: 7 | Pages: 4299-4308

10.1093/rheumatology/keaf062 | PMID 40088930 Get It

Abstract Objectives To determine the efficacy, safety and pharmacodynamics of belumosudil in patients with diffuse cutaneous systemic sclerosis (dcSSc) treated with background immunosuppressive therapies. Methods Eligible patients were randomised 1:1:1 to receive belumosudil 200 mg once daily (QD) or twice daily (BID), or placebo for 28 weeks (double-blind period). After unblinding, the patients who received belumosudil continued the same dose, whereas the patients who received placebo were re-randomised for one of the belumosudil doses for 24 weeks (open-label extension). Results Thirty-five and 31 patients were treated in the double-blind and open-label periods, respectively. The study was terminated prematurely, and target enrolment was not met. The primary end point, of CRISS score ≥0.60 at week 24, did not exhibit an efficacy signal in the belumosudil vs placebo groups [odds ratio: 1.06 (0.19–5.82; P = 0.9472) for the QD, and 0.39 (0.07–2.35; P = 0.3078) for the BID group]. Belumosudil was well tolerated and exhibited similar safety profiles in both double-blind and open-label periods. Tissue-based RNA sequencing analysis revealed FOXP3 upregulation and STAT3, IL23A and TGF-β downregulation in patients with CRISS score ≥0.60, which supported the mechanism of action of belumosudil. In blood and tissue samples, trends of decreased fibrosis biomarker levels were seen in the belumosudil-treated group vs placebo. Conclusion Efficacy signal for belumosudil could not be detected. Signalling pathway modulation analysis supported the mechanism of action of belumosudil. A trend for decreased fibrosis-related biomarkers was observed in the belumosudil-treated group. Trial registration ClinicalTrials.gov, https://clinicaltrials.gov, NCT03919799.
Pitfalls and Strategies for Implementing and Sustaining an Otolaryngology Perioperative Registry in Mekelle, Ethiopia
Cortes, Mateo Mauricio Useche , Eyassu, Daniel G. , Rincón-Gómez, Ariana Sofia , Hable, Nicholas, Yehala, Zaid M., Asgedom, Brhanu H. , Wiedermann, Joshua P. , Useche, Mateo , Rincon, Ariana S , Hable, Nicholas

Mayo Clinic

Annals of Otology, Rhinology & Laryngology | March 15, 2025 | Volume: 134 | Issue: 7 | Pages: 540-544

10.1177/00034894251326007 | PMID 40087917 Get It

Background: Surgical registries have been widely adopted in high-income countries to improve patient outcomes. However, similar data-driven initiatives are still scarce in low- and middle-income countries (LMICs). Aims: This study aimed to address the challenges of implementing a perioperative registry for otolaryngology-head and neck surgery (OHNS) in Mekelle, Ethiopia, and to assess strategies for ensuring its long-term sustainability. Methods: The registry was developed using REDCap, through a collaborative effort between otolaryngologists in the United States and Ethiopia, ensuring its relevance to the local context. On-site training sessions were conducted for 13 OHNS residents and four senior surgeons to facilitate their use of the registry. A Wi-Fi router was installed in the operating room to enable real-time data entry. Continuous support was provided through remote communication between the local team and the U.S. research team. Sustainability strategies focused on fostering local ownership, integrating the registry into existing workflows, and maintaining continuous data monitoring. Results: Despite facing challenges like intermittent internet connectivity and issues with workflow integration, the local team successfully integrated the registry into routine clinical and surgical practices. Key strategies included providing dedicated Wi-Fi routers, modifying registry fields for improved efficiency, and emphasizing the registry’s value to the institution. Ongoing collaboration between the local team and the U.S. team enabled continuous optimization and data collection. Conclusion: The successful implementation of this perioperative registry underscores the importance of engaging local stakeholders and integrating sustainable workflows. This initiative serves as a model for other LMICs seeking to establish surgical registries that enhance data-driven decision-making at both the patient and institutional levels.
Arthroscopic Hip Labral Reconstruction and Augmentation—Retro TAPT: Retrograde Passage, Tie Anterior to Posterior, and Truncate
Cabarcas, Brandon C. , Reuter, Zachary C. , Ina, Jason , Krych, Aaron J. , Hevesi, Mario , Cabarcas, Brandon , Krych, Aaron J , Hevesi, Mario , Ina, Jason G , Ward, Gavin H.

Mayo Clinic

Arthroscopy Techniques | March 14, 2025 | Volume: 14 | Issue: 6 | Pages: No page available

10.1016/j.eats.2025.103514 | PMID 40656683 Get It

Abstract The standard of care for hip labral tears is arthroscopic repair, with labral reconstruction performed more commonly for irreparable tears in order to avoid isolated labral debridement. However, labral reconstruction can be technically demanding. We provide a concise step‐by‐step guide for performing labral reconstruction or augmentation using a modified retrograde pull‐through technique, including tips, tricks, and surgeon pearls, and pitfalls. Despite the procedure's technically challenging nature, we believe our technique highlights several important steps to improve the practicality and efficiency of the case and produce satisfactory patient outcomes. Technique Video video See video under supplementary data.
Associations between neuropsychiatric symptoms and pathology in clinicopathologically defined Alzheimer's disease, Alzheimer's disease with Lewy bodies, and dementia with Lewy bodies
Tremblay, Cécilia , Shakir, Neha , Zhang, Nan , Adler, Charles H. , Shill, Holly A. , Mehta, Shyamal H. , Driver‐Dunckley, Erika , Belden, Christine M. , Beach, Thomas G., Mehta, Shyamal , Serrano, Geidy E , Choudhury, Parichita , Belden, Christine , Adler, C H , Atri, Alireza , Beach, Thomas G. , Serrano, Geidy E. , Choudhury, Parichita

Mayo Clinic

Journal of Alzheimer’s Disease | March 14, 2025 | Volume: 104 | Issue: 3 | Pages: 933-942

10.1177/13872877251320670 | PMID 40084663 Get It

Background Neuropsychiatric symptoms (NPS) are frequent in Alzheimer's disease (AD) dementia, but a higher NPS burden is found in dementia with Lewy bodies (DLB). Lewy body (LB) pathology frequently co-occurs with AD pathology and may not meet neuropathological criteria for DLB (ADLB). NPS trajectories over disease course in these subgroups is not well understood. Objective We investigated changes in NPS severity over time, at two time points, comparing clinicopathologically defined cohorts of AD (without LB), ADLB, DLB, and controls. Methods Cases with two available Neuropsychiatric Inventory-Questionnaire (NPIQ), at the time of enrollment and within 2.5 years of death, were selected from the Arizona Study of Aging and Neurodegenerative Disorders. Differences and rate of change in NPIQ scores were compared between AD (n = 75), ADLB (n = 48) DLB (n = 65), and controls (n = 32) with covariates for age, sex, and cognition. Results First NPIQ scores were highest in ADLB when compared to AD (p = 0.04) and controls (p = 0.01) but not different from DLB. A significant increase in NPS severity was observed in DLB and AD (p < 0.001) over a mean follow up time of 4.9 ± 3.0 years, and the rate of change was significantly greater in DLB when compared to other groups. Final NPIQ scores were highest in DLB when compared to AD (p = 0.03) but not ADLB, and in DLB, ADLB, and AD than controls ( all p < 0.001). Conclusions Early NPS burden as well as NPS severity progression rate, independently of cognitive status, might be useful clinical metrics and may help predict underlying pathological diagnoses.
Inducing immunity? Justifying immunization policies in times of vaccine hesitancy By RolandPierik and MarcelVerweij, Cambridge, MA: The MIT Press. 2024. pp. 248. US $45.00. (Paperback). ISBN: 9780262547796
Gadri, Dorcas, Gur‐Arie, Rachel , Meagher, Karen M. , Meagher, Karen M

Mayo Clinic

Bioethics | March 13, 2025 | Volume: 39 | Issue: 5 | Pages: 519-522

10.1111/bioe.13405 Get It